Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

This is an interventional treatment trial for Pancreatic Cancer focused on measuring Metastatic pancreatic cancer, Metastatic pancreatic adenocarcinoma that is recurrent Read More

Inclusion Criteria:

• Histologically or cytologically confirmed adenocarcinoma of the pancreas.
• Advanced adenocarcinoma of the pancreas that is inoperable or metastatic.
• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
• Received 1 prior chemotherapy regimen for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy).
• ≥ 2 weeks elapsed from the completion of previous treatment regimen and participants must have recovered or be at a new stable baseline from any related toxicities.
• Radiographically measurable or evaluable disease

• Modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:

  1. mGPS of 1: C-reactive protein >10 mg/L and albumin ≥35 g/L
  2. mGPS of 2: C-reactive protein >10 mg/L and albumin <35 g/L

Exclusion Criteria:

• Received more than 1 prior regimen for advanced or metastatic disease.
• Ongoing radiation therapy, radiation therapy administered within 30 days of enrollment.
• Concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, investigational therapy, or tumor embolization).
• Prior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase deficiency (DPD), or other known hypersensitivity to active substances, including fluorouracil (5-FU), or ruxolitinib, or any of their excipients.
• Prior treatment with a JAK inhibitor for any indication.